eMJA: Successful implementation of cardiometabolic monitoring of patients treated with antipsychotics

To the Editor: A recent article in the Journal describes, again, barriers to implementation of cardiometabolic monitoring among patients prescribed antipsychotic drugs.1 The cardiac health of patients with psychosis is not routinely assessed at first presentation for mental health services, adverse side effects of antipsychotic drugs are not systematically monitored, and patients with treatable risk factors for heart disease are not identified.2

NB: If you are registered with the eMJA, your username is the email address you have provided.
If you don't have a login, click here for subscription options. You will be prompted to create an account upon purchase.

AMA members can login using their AMA username and password.
If you don't know your AMA password, please contact the AMA on 02 6270 5400 or membership@ama.com.au, or try to retrieve your password at this address.

-->

The Medical Journal of Australia eMJA

Username:
Password:

Password forgotten? Click here What is my username?